Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

Recurrent Glioblastoma Clinical Trial

Official title:

An Exploratory Study on Camrelizumab Combined With Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04952571
• Other study ID #: OBU-BJ-GBM-II-007
• Status: Suspended
• Phase: Phase 2
• Start date: May 1, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: July 2023
• Source: Beijing Sanbo Brain Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is intend to explore the efficacy and safety of combined treatment of camrelizumab and bevacizumab in adult patients with recurrent glioblastoma.

Description:

There is no effective chemotherapy regimen for recurrent glioblastoma. The antiangiogenic drug bevacizumab has high objective response rate and rapid onset, but the duration of efficacy needs to be improved.The objective response rate of PD-1 monoclonal antibody immunotherapy is low and the onset of the effect is slow, but the effective patients have a long duration of efficacy.The combined treatment of PD-1 monoclonal antibody and bevacizumab may learn from each other to improve the effective rate, shorten the onset time and prolong the duration of efficacy.Studies have shown that bevacizumab can enhance the efficacy of immunotherapy in a variety of cancers, including melanoma, kidney cancer, non-small cell lung cancer, and liver cancer.However, previous studies have shown limited efficacy of PD-1 monoclonal antibody combined with bevacizumab in the treatment of recurrent glioblastoma.

In this study, the combination therapy was optimized by introducing induction phase therapy, which is expected to further improve the efficacy. In our previous exploratory treatment of patients with severe recurrent glioblastoma after multiple treatments, the initial efficacy was considerable.

The purpose of this study is to evaluate the efficacy and safety of camrelizumab [a programmed cell death 1 (PD-1) inhibitor] combined with bevacizumab for adult patients with recurrent glioblastoma.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 94
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age 18~70, male or female

2. Primary supratentorial glioblastoma with first or second rogression/recurrence

3. IDH1/2 wildtype

4. KPS score =70 in patients with the first recurrence and =60 in patients with the second recurrence

5. Expected survival =12 weeks.

6. The time interval from the last radiotherapy was =12 weeks, unless there was new tumor enhancement in the radiological field or clear evidence of tumor hipathology.

7. Radiotherapy and at least one regimen of chemotherapy before recurrence (excluding temozolomide chemotherapy during concurrent radiotherapy).

8. The patients were enrolled after the end of the previous chemotherapy interval and had recovered from the related adverse reactions (except hair loss and pigmentation).

9. The tumor was confirmed to have definite recurrence by MRI, with enhanced lesion diameter =1cm and =2 layers (layer spacing 5mm), or was confirmed to have recurrence by pathology after re-biopsy or surgery.

10. The time interval between the last operation and the last biopsy was =4 weeks or =2 weeks at the time of enrollment.

11. The main organs function normally, no serious abnormal blood, heart, lung, liver, kidney function and immune deficiency diseases

12. Women of childbearing age are required to have a negative pregnancy test (serum or urine) within 7 days before enrolment and to voluntarily use contraception during treatment and within 8 weeks after the last treatment;For men, they should be surgically sterilized or agree to use contraception during treatment and for 8 weeks after the last treatment.

13. Patients voluntarily enrolled in this study and signed informed consent (ICF).

14. Good compliance is expected, efficacy and adverse reactions can be followed up according to protocol requirements

Exclusion Criteria:

1. Glioblastoma in the midline (thalamus, brainstem, sellar region, etc.).

2. Patients with initial recurrence had previously received long-term high-dose antiangiogenic drugs (except those with amlotinib or apatinib for less than 1 month and no progress during treatment, except those with intermittent bev dose intensity =5mg/ week and =3 times) or immunocheckpoint inhibitors, TCR-T, CAR-T, etc.;Patients with secondary recurrence had previously received long-term high-dose therapy of Bev (except for intermittent Bev dose intensity =5mg/ week and =3 times) or immunocheckpoint inhibitors, TCR-T, or CAR-T.

3. Other study drugs are being used.

4. An allergic reaction or intolerance to any component of the drug used in this study is known.

5. Other malignant tumors in the past 3 years.

6. Subjects who had been systematically treated with corticosteroids (>4mg/day dexamethasone or other equivalent hormone) or other immunosuppressants within 2 weeks prior to first use of carrelizumab.In the absence of active autoimmune disease, inhaled or topical corticosteroids and hormone replacement therapy with doses less than or equal to 4mg/ day of dexamethasone are permitted.

7. The presence or history of any active autoimmune disease .

8. Uncontrolled hypertension.

9. Myocardial infarction occurred within 6 months prior to enrollment, New York Heart Society Class II heart failure or above, uncontrolled angina pectoris, uncontrolled severe arrhythmias, clinically significant pericardial disease, and electrocardiogram indicating acute ischemia or abnormal active conduction system.

10. Abnormal coagulation function, bleeding tendency or receiving thrombolytic or anticoagulant therapy.

11. Before entering the study 3 months there have been significant clinical significance of bleeding symptoms or have definite bleeding tendency;Or arterial/venous thrombosis events, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, occurred within 6 months before the study.

12. Severe infection occurred within 4 weeks prior to initial administration;Or unexplained fever >38.5? during screening/prior to first administration.

13. People who have a history of abuse of psychotropic substances and are unable to get rid of them or have mental disorders.

14. Had major surgery or had an open wound or fracture within 4 weeks prior to first administration.

15. Empty sinus passages or perforations were observed within 6 months prior to study entry.

16. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBVDNA=500IU/ mL), hepatitis C (positive hepatitis C antibody and HCV-RNA above the detection limit of the assay method) or co-infection with hepatitis B and hepatitis C.

17. Patients who received anti-tumor vaccine or other immunomodulatory drugs within 4 weeks before enrolment;Patients who have received or will receive live attenuated or recombinant vaccine within 4 weeks;Patients who received or will receive the inactivated vaccine within 1 week.

18. Pregnancy and lactation.

19. Other conditions that the investigator considered inappropriate for inclusion.

Related Conditions & MeSH terms

• Glioblastoma
• Recurrence
• Recurrent Glioblastoma

Intervention

Drug:
• Camrelizumab and Bevacizumab
Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total. Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion.

Locations

Country	Name	City	State
China	Beijing Sanbo Brain Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Sanbo Brain Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival rate at 6 months	Progression-free survival rate at 6 months	Up to three years
Secondary	OS(overall survival)	the time interval from entry to death from any cause or last follow-up and is measured in the intent-to-treat population	Up to three years
Secondary	PFS(progression free survival)	the time interval from entry to tumor progression, death from any cause, or last follow-up	Up to three years
Secondary	ORR(objective response rate)	rate of CR+PR	Up to three years
Secondary	DCR(Disease Control Rate)	rate of CR+PR+SD	Up to three years
Secondary	The correlation between KPS change and efficacy	the correlation between KPS baseline, KPS change (increase, decrease,stable) and best efficacy (CR, PR, SD, PD).	Up to three years
Secondary	Median duration of KPS = 70	Median duration of KPS = 70 during progression-free survival	Up to three years
Secondary	Frequency and severity of treatment-related adverse events	Frequency and severity of treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Up to three years
Secondary	Median duration of stable/improved quality of life assessed by EORTC QLQ-C30	the time interval from entry to change of =10 points on the EORTC QLQ-C30 without further improvement or disease progression or death.	Up to three years
Secondary	Median duration of stable/improved quality of life assessed by EORTC QLQ-BN20	the time interval from entry to change of =10 points on the EORTC QLQ-BN20 without further improvement or disease progression or death.	Up to three years